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Polyethylene glycola b s t r a c t
Ligand conjugation is an attractive approach to rationally modify the poor pharmacokinetic behavior and
cellular uptake properties of antisense oligonucleotides. Polyethylene glycol (PEG) attachment is a
method to increase solubility of oligonucleotides and prevent the rapid elimination, thus increasing
tissue distribution. On the other hand, the attachment of long PEG chains negatively inﬂuences the phar-
macodynamic effect by reducing the hybridization efﬁciency. We examined the use of short PEG ligands
on the in vitro effect of antisense agents. Circular dichroism showed that the tethering of PEG12-chains to
phosphodiester and phosphorothioate oligonucleotides had no inﬂuence on their secondary structure
and did not reduce the afﬁnity to the counter strand. In an in vitro tumor model, a luciferase reporter
assay indicated unchanged gene silencing activity compared to unmodiﬁed compounds, and even slightly
superior target down regulation was found after treatment with a phosphorothioate modiﬁed conjugate.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).During the last years, the therapeutic development of oligonu-
cleotides has experienced several important advances. For the ﬁrst
time, a systemically applied oligonucleotide, mipomersen, has won
market approval.1,2 Promising clinical data have been reported for
treatment of Duchenne muscular dystrophy by the splice-
switching oligonucleotides eteplirsen.3 siRNA-based agents have
recently entered clinical testing, and many new or optimized oligo-
nucleotide delivery systems have been evaluated preclinically.4,5
Thus, good progress has been made in terms of solving the delivery
problem for local administration, and also for hepatocyte targets;
all clinically successful approaches use systems with preferential
accumulation in the liver. In addition, the expanding knowledge
of the multifold roles of endogenous small non coding RNAs, above
all microRNAs,6–9 have increased the potential therapeutic options
and targets of oligonucleotide medicines.
For the delivery of siRNA and miRNA-like oligonucleotides, the
limited tolerance of the molecular RNAi machinery all but prevents
the use of oligonucleotides that are chemically modiﬁed to a
degree which allows naked application.5 In these cases, encapsula-
tion or complexation with liposomes or nanoparticles or conjuga-
tion to uptake-enhancing agents are essentially required.4,10 For
antisense and splice-switching applications, however, the use of
more drastically derivatized compounds, which confer adequatestability against nuclease degradation and favorable binding to
plasma proteins, is possible.1,11
Recently, we have reported the inﬂuence of the attachment of
short PEG chains to siRNA oligonucleotide on their gene silencing
efﬁciency.12 In contrast to long PEG chains, which result in
adequate shielding against nuclease degradation, but reduce the
gene silencing effect,13 shorter ligands with twelve ethylene glycol
units did not diminish the effect. PEGylation even resulted in
enhanced gene silencing for an siRNA which had only average
efﬁciency in its wild-type form.12
While antisense and siRNA oligonucleotide differ in the
molecular machinery, their physicochemical properties are very
similar. Antisense oligonucleotides proﬁt from vast possibilities
of modifying their chemical structure without signiﬁcant loss of
activity.11 Among those modiﬁcations, the phosphorothioate back-
bone has been proven to be particularly useful, because it enhances
cell membrane permeation.14 Thus, we examined the effect of
short PEG chains on the in vitro gene silencing activity both after
application with a transfection agent and after unassisted cellular
uptake of phosphodiester and phosphorothioate antisense agents.
Aminohexyl linkers were introduced into oligonucleotides
targeted at galectin-1 and bcl-2 at the 30- and 50-position via a
commercially available modiﬁed solid phase and a phosphorami-
dite building block, respectively (Table 1). Oligonucleotide synthe-
ses were carried out using standard DNA synthesis protocols and
reagents. For phosphorothioate syntheses, TETD (tetraethylthiu-
ramdisulﬁde) was used as the sulfurization reagent.15 For
Table 1
Oligonucleotide sequences targeted at galectin-1 (1–6) and bcl-2 (7–10)
No. Sequence Strand Modiﬁcation
1 TTCGTATCCATCTGGCAGC AS —
2 PEG-TTCGTATCCATCTGGCAGC AS 50-PEG
3 TTCGTATCCATCTGGCAGC-PEG AS 30-PEG
4 TTCGTATCCATCTGGCAGC AS Full PS
5 TTCGTATCCATCTGGCAGC-PEG AS Full PS, 30-PEG
6 GCTGCCAGATGGATACGAA S —
7 TCTCCCAGCGTGCGCCAT AS —
8 PEG-TCTCCCAGCGTGCGCCAT AS 50-PEG
9 TCTCCCAGCGTGCGCCAT-PEG AS 30-PEG
10 ATGGCGCACGCTGGGAGA S —
Figure 1. CD spectra of PEGylated antisense oligonucleotide duplexes. The
indicated oligonucleotides were mixed in an equimolar ratio with their counter-
strand 6 in a tris buffer solution and subjected to circular dichroism analysis.
Table 2
Duplex transition temperatures of PEGylated oligonucleotides.
Oligonucleotide Melting temperaturea
1 + 6 80.73 ± 0.30
2 + 6 78.30 ± 0.22
3 + 6 79.40 ± 0.57
4 + 6 64.67 ± 0.76
5 + 6 65.83 ± 0.85
7 + 10 85.70 ± 0.71
9 + 10 86.75 ± 1.26
a Values are reported as average ± SEM of at least three independent
measurements.
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50-amino tethers were introduced with a corresponding
aminohexyl phosphoramidite. Cleavage and full deprotection were
afforded in concentrated ammonia at 55 C for 16 h. In contrast to
the experience with AMA deprotection for siRNA (longer reaction
times were necessary for full hydrolysis of the amino protecting
group),12 the 30-amino tether was fully deprotected during stan-
dard ammonia treatment.
These linkers were then used as attachment points for NHS-
activated PEG12 units (Scheme 1). For a nearly quantitative yield
after 2 h reaction time, a 50fold surplus of the NHS-PEG ligand
was added from a stock solution in anhydrous DMF to the oligonu-
cleotide dissolved in sodium borate buffer. The unreacted PEG
ligand was removed from the mixture by gel ﬁltration, and the
PEGylated oligonucleotide was puriﬁed by preparative gel electro-
phoresis. Analyses on gel electrophoresis (Scheme 1) and HPLC
conﬁrmed product purities.
Circular dichroism spectra were recorded to detect a possible
inﬂuence of the ligands on the structural properties of the paired
oligonucleotide duplexes. Neither 30- nor 50-attachment changed
the curve shape (Fig. 1). The slightly higher band intensities even
indicate a small stabilization of the duplex structure caused by
the PEGylation. Similar results were found for the phosphorothio-
ate oligonucleotides 4 and 5 (data not shown).
For an assessment of the target afﬁnity, the duplex transition
temperatures (melting temperatures) of the PEGylated oligonucle-
otides were compared to those of the unmodiﬁed ones (Table 2).
Generally, only a very minor destabilization was detected for oligo-
nucleotides with phosphodiester backbones (2 and 3) compared to
non-PEGylated duplexes. For phosphorothioate backbone modiﬁed
compounds, the transition temperature was about 1 C higher
when the PEG chain was attached. In line with known properties,
the melting temperature of phosphorothioates were about 15 CScheme 1. Chemical conjugation scheme of short PEG chains to antisense oligonucleo
antisense oligonucleotides at the 30- or 50-terminus. After cleavage and deprotection, the a
surplus of the PEG ligand, the reaction proceeded nearly quantitatively after 2 h. (B) The a
denaturing polyacrylamide gel. The gel shows a representative image of the reaction of a 3
left to right; 0 min, 30 min, 120 min reaction time).lower than for their phosphodiester counterparts.16 Together with
the CD data, it can be concluded that the 30-and 50-short PEG
ligands do not interfere with recognition and they do not inﬂuence
the target afﬁnity. Based on the data and the lack of intrastrand
modiﬁcations, it can be safely assumed that the RNase H activation
ability is not affected by the ligands.
The gene silencing activity was evaluated in vitro with a lucifer-
ase reporter assay. In analogy to the reported psiCHECK2-bcl-2
plasmid,12 we generated a luciferase reporter plasmid for assaying
the silencing effect on galectin-1, a promising oncology target.17 It
was generated by cloning the human galectin-1 cDNA into the
empty psiCHECK2 vector.12 The renilla luciferase intensity
corresponds to the expression of the target gene, while ﬁreﬂy lucif-
erase is used for normalization of transfection efﬁciency. Fortides. (A) During oligonucleotide synthesis, aminohexyl linkers were attached to
mines were reacted with PEG12-NHS reagent in an aqueous buffer solution. Using a
ttachment reaction was monitored by taking samples with subsequent analyses on a
0-aminohexyl phosphorothioate antisense oligonucleotide to give conjugate 5 (from
5760 N. Shokrzadeh et al. / Bioorg. Med. Chem. Lett. 24 (2014) 5758–5761reverse co-transfections of antisense or siRNA oligonucleotides
with the psiCHECK2 plasmid, lipofectamine 2000 was used, and
luminescence intensities were measured with the Dual Luciferase
Assay Kit from Promega. For application of oligonucleotides in
the absence of a transfection reagent, the plasmid was reverse
transfected, the transfection mix removed after 24 h, and fresh
medium containing the indicated amounts of oligonucleotides
was added.
Breast cancer cells MCF-7 were treated with both phosphodiest-
ers (1 and 3) and phosphorothioates (4 and 5) with and without 30-
PEG ligand (Fig. 2). After co-transfection with lipofectamine 2000,Figure 2. Effect of PEGylated phosphorothioate antisense oligonucleotides in a
luciferase reporter assay after transfection with lipofectamine 2000 (A) and after
naked application (B). For transfections, the indicated oligonucleotides were mixed
with the psiCHECK-2-Gal-1 plasmid encoding renilla luciferase fused to the human
cDNA of galectin-1, and the ﬁreﬂy luciferase for normalization. The mixture was co-
transfected into the breast cancer cell line MCF-7 and after 48 h incubation, the
luminescence levels were recorded in a plate reader. For the evaluation of
unassisted cellular uptake, the plasmid was ﬁrst transfected into the cells, and
24 h later the oligonucleotides were added into fresh medium. Luminescence levels
were analyzed after a 48 h incubation period. Values are reported as renilla
normalized to ﬁreﬂy luciferase signals (n = 3, error bars are SEM). In co-transfec-
tions, the phosphorothioate conjugate 5 showed higher efﬁcacy compared to the
isosequential oligonucleotide 4 (100 nM, p < 0.05), but no inﬂuence of the
PEGylation on gene silencing activity was found after naked application (gymnotic
uptake).all tested oligonucleotides resulted in signiﬁcant gene silencing
(Fig. 2A, p < 0.05). Neither statistically signiﬁcant enhancement
nor decrease of the effect was detected by the PEGylation of the
phosphodiester backbone compound. In contrast, the PEGylated
phosphorothioate 5 showed higher gene silencing activity than
its non-PEGylated counterpart 4 after transfection in a concentra-
tion of 100 nM (p < 0.05).
In order to assess the effect on cellular uptake, the gene silenc-
ing efﬁciency was evaluated after application of the uncomplexed
agents (Fig. 2B) in the presence of serum. As expected, all phospho-
diesters failed to induce any effect on the expression of the
targeted gene, presumably caused by rapid degradation through
serum nucleases and the inability of the compounds to permeate
cellular membranes. The phosphorothioate oligonucleotides with
and without a PEG ligand resulted in moderate target down
regulation after treatment in a concentration of 100 nM. In line
with their known properties, the phosphorothioate backbone
enhances cellular uptake.14 Indicated by the same extent of gene
silencing by the oligonucleotides 4 and 5, the polyethylene glycol
ligand failed to signiﬁcantly further enhance the membrane
permeation properties of the antisense agent.
To exclude any unspeciﬁc or toxic effects, cell proliferation rates
were assessed after treatment with the modiﬁed oligonucleotides,
applied without transfection enhancer (Fig. 3). In concentrations
that resulted in successful gene silencing, none of the oligonucleo-
tides reduced proliferation by more than 15%, with a 13% reduction
caused by non-PEGylated phosphorothioate 7 (100 nM) being the
most pronounced effect. Thus, PEGylation did not induce any
negative effect on proliferation, indicating a good in vitro safety
proﬁle of the conjugates.
In total, we have shown that antisense oligonucleotides can be
modiﬁed with short PEG12 chains at the 30-and 50-end without any
loss in gene silencing activity, indicating a tolerance of the molec-
ular effector RNase H towards this derivatization. Although the
unassisted cellular uptake is not signiﬁcantly enhanced through
this short amphiphilic chain, gene silencing was increased after
administration in 100 nM concentration when used in conjunctionFigure 3. Effect of PEGylated phosphorothioate antisense oligonucleotides on cell
proliferation. To evaluate unspeciﬁc toxicity, cell proliferation rates were assayed
after treatment with antisense oligonucleotides. The indicated compounds were
applied without transfection reagents, and proliferation was evaluated after a 24 h
incubation period with an MTS assay.18 No signiﬁcant inﬂuence on proliferation
was detected for any compound, indicating no apparent toxic effects caused by the
PEG conjugations (n = 3, error bars are SEM).
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siRNA, for which the short PEG ligands improved the effect in some
cases.12 It can be speculated that these outcomes are caused by
higher stability and/or better endosomal escape through the
amphiphilic ethylene glycol. The PEG attachment is structurally
and synthetically compatible with other chemical modiﬁcations,
including backbone derivatization, 20-functionalization and even
30-or 50-bioconjugation techniques. This easily introduced
modiﬁcation by itself is not sufﬁcient for signiﬁcantly improving
the pharmacokinetic and pharmacodynamic characteristics of anti-
sense agents, because the short PEG chain will not prevent renal
ﬁltration.11 Thus, although not suited as a stand-alone modiﬁcation
for delivery, it may be a useful component towards enhancing oli-
gonucleotides by chemical derivatization or in combination with
oligonucleotide delivery systems.
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